CordIn is under clinical development by Gamida Cell and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CordIn’s likelihood of approval (LoA) and phase transition for Aplastic Anemia took place on 19 Jul 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 19 Jul 2022 decreased CordIn’s LoA and PTSR for Myelodysplastic Syndrome.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CordIn Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CordIn overview

CordIn is under development for the treatment of hemoglobinopathies including aplastic anemia and hypo-plastic myelodysplastic syndrome. It is administered as an intravenous infusion. The therapeutic candidate is CD133+ cells derived from allogenic umbilical cord blood cells. The drug candidate is developed based on NAM platform technology. It was under development for sickle cell disease and beta thalassaemia.

Gamida Cell overview

Gamida Cell (Gamida) is a health care company. It offers cell therapy developing cell and immune therapy technologies for treating blood cancers and serious blood disorders. Its pipeline products include Omidubicel an advanced cell therapy being developed as an allogeneic hematopoietic stem cell (bone marrow) transplant solution for treating hematologic malignancies and severe aplastic anemia; GDA-201 an innate natural killer cell immunotherapy used for the treatment of hematologic and solid tumors. Gamida utilizes NAM technology platform to develop its products. Gamida is headquartered in Jerusalem, Israel.

Quick View CordIn LOA Data

Report Segments
  • Innovator
Drug Name
  • CordIn
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Hematological Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.